UNSPSC 51142518: Apomorphine or apomorphinum

This classification denotes a dopamine agonist and antiparkinsonian agent with the molecular formula C17H17NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N21FAR7B4S, chemically known as 6a.beta.-noraporphine-10,11-diol, 6-methyl-, hydrochloride but generally known as apomorphine, which bears US NIH Compound Identifier 2215. Apomorphine most often comes in base, chloride, diacetate, hydrochloride, and hydrochloride hemihydrate forms.

European Medicines Agency schedules Apomorphine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12923MIG. World Health Organization schedules apomorphine in its Anatomical Therapeutic Chemical (ATC) Classification. Apomorphine or apomorphinum bears US NLM identifiers UMLS ID C0003596 and NCI Concept Code C61639. SMILES: OC1C2C3C4C(N(CCC4CCC3)C)CC2CCC1O.

UNSPSC 51142518 Apomorphine or apomorphinum is a Commodity code for pharmaceutical products, but the single recent state-local opportunity on record—Seminole County, Florida's IFB60459723LAS—does not involve apomorphine procurement; instead, it solicits naloxone and drug deactivation systems for community health initiatives. This mismatch suggests the code has little relevant recent activity in state and local procurement channels, or that issuing bodies are tagging opportunities inconsistently against the UNSPSC taxonomy.

Seminole County posted the naloxone and drug deactivation systems procurement on June 30, 2026, as an Invitation for Bid (IFB) with a response deadline of July 26, 2023, requesting 1,900 units of naloxone and 800 safe drug deactivation systems annually via quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. Vendors were required to submit bids electronically through the county's e-Procurement Portal, include all shipping and delivery costs, and comply with federal and state employment verification, drug-free workplace, and insurance requirements. The contract term was two years with an option for one-year renewal and included a three-month probationary termination window. Beyond this single solicitation, the source provides no evidence of broader state-local procurement activity under the apomorphine code, no additional jurisdictions, and no issuing-body pattern.